Orthocell (ASX:OCC) - Managing Director, Paul Anderson (left)
Managing Director, Paul Anderson (left)
Source: Orthocell
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Regenerative medicine company Orthocell (OCC) secures Chinese and New Zealand patents for its novel CelGro collagen medical device 
  • The patents, titled “Sutureless repair of soft tissue”, are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe
  • The patents are set to expire on 12 October 2035
  • Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.

The patents, titled “Sutureless repair of soft tissue,” are now approved in Australia, New Zealand, China and Japan, with further applications progressing in US and Europe.

Sutureless repair of soft tissue means repairing damaged soft tissue without the use of damaging stitches.

Orthocell said sutureless repair had the potential to greatly improve the efficiency of surgical procedures by simplifying techniques, reducing surgery time and reducing the risk of additional trauma to soft tissue caused by the use of stitches.

Orthocell’s patented method of sutureless repair involves the use of CelGro, the company’s resorbable collagen medical device. CelGro acts as a cell scaffold when implanted at the site of tissue injury, encouraging new cell growth. Cells from the regenerating tissue integrate with the collagen fibres to guide tissue regeneration.

“These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair,” Orthocell Managing Director Paul Anderson said.

“This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, European Union and Australia.”

The patents are set to expire on 12 October 2035.

Orthocell was up 1.77 per cent, trading at 57.5 cents per share at 11:45 am AEST.


OCC by the numbers
More From The Market Online
Disability NDIS concept

Freedom Care Group reveals NDIS wants to ban it providing program services

Shares in Freedom Care Group (ASX:FCG) were down more than -3% on Wednesday after revealing the…
Image representing bacterial infections in the immune system

Recce reaches key dosing milestone in testing of skin infection gel

Recce Pharmaceuticals Ltd has successfully dosed 20 out of 30 participants in its Phase II trial…
Bank of England London town

Wellnex bumps first $3M payment for Pain Away into 1Q25 – when it lists in London

Wellnex Life Ltd (ASX:WNX) has unveiled its plans to defer a $2.95M payment to 360 Health…
DNA RNA therapy concept

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11,…